Bellissant E, Duhamel J F, Guillot M, Pariente-Khayat A, Olive G, Pons G
Université René Descartes, Paris V, France.
Clin Pharmacol Ther. 1997 Mar;61(3):377-84. doi: 10.1016/S0009-9236(97)90170-3.
Sequential methods are particularly interesting when recruitment is difficult because they may allow a study to be stopped early while maintaining type I and II error rates.
This placebo-controlled, randomized double-blind study was aimed at assessing the efficacy of metoclopramide (0.2 mg/kg three times daily during 14 days) on gastroesophageal reflux in infancy. The main end point was the relative variation of the percentage of time at pH < 4 between inclusion (day 0) and evaluation (day 14) assessed on two 24-hour esophageal pH recordings. Statistical analysis was performed with use of a sequential method, the triangular test.
The study was stopped after the seventh analysis (39 infants evaluated: 20 placebo and 19 metoclopramide) without showing the expected benefit. Improvement on the main end point was 30% +/- 48% (mean +/- SD). Corresponding unbiased median estimates were 22% for placebo and 39% for metoclopramide (p = 0.28, sequential analysis). On day 14, the percentage of time at pH < 4 was 8.1% +/- 11.7% for placebo and 6.7% +/- 9.2% for metoclopramide (p = 0.68, t test), and the number of reflux episodes > 5 minutes was 3.0 +/- 3.5 for placebo and 1.9 +/- 3.0 for metoclopramide (p = 0.33, t test).
If a tendency for a superior improvement with metoclopramide than with placebo was observed on the main end point, it was lower than expected and the difference was not significant. Compared with the corresponding single-stage design, the triangular test allowed to stop the study with a 15% reduction in sample size.
当招募困难时,序贯方法特别有意义,因为它们可能允许在维持Ⅰ型和Ⅱ型错误率的同时提前终止研究。
这项安慰剂对照、随机双盲研究旨在评估甲氧氯普胺(0.2mg/kg,每日3次,共14天)对婴儿胃食管反流的疗效。主要终点是在纳入(第0天)和评估(第14天)时,通过两次24小时食管pH记录评估的pH<4的时间百分比的相对变化。使用序贯方法(三角检验)进行统计分析。
在第七次分析后(评估了39名婴儿:20名安慰剂组和19名甲氧氯普胺组)研究终止,未显示出预期的益处。主要终点的改善为30%±48%(均值±标准差)。相应的无偏中位数估计值为安慰剂组22%,甲氧氯普胺组39%(p = 0.28,序贯分析)。在第14天,安慰剂组pH<4的时间百分比为8.1%±11.7%,甲氧氯普胺组为6.7%±9.2%(p = 0.68,t检验),反流发作>5分钟的次数安慰剂组为3.0±3.5,甲氧氯普胺组为1.9±3.0(p = 0.33,t检验)。
尽管在主要终点上观察到甲氧氯普胺比安慰剂有更好改善的趋势,但低于预期且差异不显著。与相应的单阶段设计相比,三角检验允许以样本量减少15%的情况下终止研究。